Fresenius Medical Care AG & Co. KGaA

NYSE:FMS

Medical - Care Facilities

Healthcare
$20.95 -0.76%

-$0.18 today

Market cap
$11.26B
Beta
0.81
P/E (TTM)
11.9
EPS (TTM)
$3.43
Dividend yield
3.65%
52W Low $20.02High $28.87

Volume 1.92M

Average 0.72M

FMS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Fresenius Medical Care AG & Co. KGaANYSE: FMS

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of €39.63M rose 4.0% year over year, ahead of the -10.1% change in trailing-twelve-month research & development. Sequentially, it rose 3.4% from the prior quarter. Over 3 fiscal years it compounded at -11.6% a year.

Context

  • Research & development amounted to 0.8% of revenue in FY2025, down 0.1 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4.0% holds above the trailing-twelve-month pace of -10.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€39.63M+3.4% QoQ
Last fiscal yearDec 2025
€157.98M-13.9% YoY
LTMJun 2026
€154.32M-10.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.0%——
1 year-13.9%——
3-year CAGR-11.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

EUR · from the income statement

Latest · FY2025
157.98M EUR
Year-over-year change
-13.9%
4-year CAGR
-8.0%

Research & Development vs competitors

How FMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.1% is the lowest of 3, against a peer median of +47.5%.
  • Research & development amounts to 0.8% of revenue for FMS, versus a peer median of 28.9%.
FMS Competitors
Research & Development for FMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TVTXTravere Therapeutics, Inc.LTM Sep 2026$245.55M USD+16.8%-3.2%37.7%
FMSFresenius Medical Care AG & Co. KGaALTM Jun 2026€154.32M EUR-10.1%-11.6%0.8%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$67.09M USD+78.1%-27.8%28.9%
DVADaVita Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding FMS) —+47.5%-15.5%28.9%

Competitors are the stored peer set for FMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.62B19.4B19.45B19.34B19.63B
Cost of Revenue12.85B14.5B14.53B14.58B14.6B
Gross Profit4.77B4.89B4.93B4.76B5.03B
Gross Margin27.1%25.2%25.3%24.6%25.6%
Research & Development220.78M228.62M231.97M183.49M157.98M
Selling, General & Admin2.77B3.17B3.2B3.14B3.03B
Operating Expenses2.92B3.38B3.56B3.29B3.2B
Depreciation & Amortization1.62B1.84B1.75B1.74B1.5B
EBITDA3.55B3.42B3.21B3.21B3.4B
EBITDA Margin20.1%17.6%16.5%16.6%17.3%
Operating Income1.85B1.51B1.37B1.47B1.83B
Operating Margin10.5%7.8%7.0%7.6%9.3%
Interest Income73.17M67.66M88.22M71.58M69.61M
Interest Expense353.6M360.14M424.64M407.04M384.41M
Other Income / Expenses(280.43M)(292.48M)(336.42M)(410.45M)(314.59M)
Income Before Tax1.57B1.22B1.03B1.06B1.51B
Pre-Tax Margin8.9%6.3%5.3%5.5%7.7%
Income Tax Expense352.83M324.95M300.56M316.06M320.97M
Net Income969.31M673.41M499M537.91M978.37M
Net Margin5.5%3.5%2.6%2.8%5.0%
EPS (Basic)0.830.570.850.921.68
EPS (Diluted)0.830.570.850.921.68
Weighted Avg Shares1.17B1.17B586.83M586.83M582.38M
Weighted Avg Shares (Diluted)1.17B1.17B586.83M586.83M582.38M

Fresenius Medical Care AG & Co. KGaA

NYSE:FMS

Intrinsic Alpha fair value

Locked

Current Price

$20.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.